

Lao PDR

Support for Vaccine: Pneumococcal conjugate vaccine (PCV) This Decision Letter sets out the Programme Terms of a Programme

1. Country: Lao PDR

2. Vaccine grant number: LAO-PCV-R

3. Date of Decision Letter: 29 September 2021

4. Date of the Partnership Framework Agreement: 07 June 2013

5. Programme title: New Vaccine Support (NVS), Pneumococcal conjugate vaccine (PCV), Routine

6. Vaccine type: Pneumococcal conjugate vaccine (PCV)

7. Requested product presentation and formulation of vaccine:

PCV13, 4 doses/vial, liquid

8. Programme duration:¹ 2013-2023

9. **Programme Budget (indicative):**(subject to the terms of the Partnership Framework Agreement, if applicable)

	2013-2020	2021	2022	2023	2024	2025	Total ²
Programme Budget(US\$)	10.650.441	72.465	206.242	44.632	-	-	10.973.780

10. Vaccine introduction grant:

Approval					
Year	Grant number	Amount (US\$)			
2013	LAO-PCV-R-VIG-MOH	150.000			

11. Product switch grant:

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

¹This is the entire duration of the programme.

²This is the total amount endorsed by Gavi for the entire duration of the programme.

³This is the amount that Gavi has approved.



Approval					
Year Grant number		Amount (US\$)			
2018	LAO-PCV-R-PSG-MOH	45.000			

12. Indicative annual amounts:3

(subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2013-2020	2021	2022
Number of vaccine doses	-	22.600	69.200
Number of AD syringes	-	22.300	72.400
Number of re-constitution syringes	-	-	-
Number of safety boxes	-	250	800
Annual Amounts (US\$)	10.650.441	139.714	206.242

13. Procurement agency: UNICEF Supply Division. The Country shall release its co-financing payments each year to UNICEF Supply Division.

14. Self-procurement:

Not applicable

Co-financing obligations:

According to the co-financing policy, the within the group:	falls	Accelerated t	ransition		
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year	2021	2022	2023	2024	2025
Number of vaccine doses	40.000	287.200	-	-	-
Number of AD syringes	39.600	300.800	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	450	3.325	-	-	-
Value of vaccine doses (US\$)	116.000	832.880		-	-
Total co-financing payments (US\$) (including freight)	119.041	855.978	-	-	-

Operational support for campaigns:

Not applicable



17. Additional Reporting Requirements:

Reports and other information :	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:	
 vaccine stock levels including buffer stock, by end of March; 	31 March
 number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. 	15 May
 Countries shall report the actual switch date in the first renewal request following the actual implementation. 	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications:

Not applicable

19. Other conditions:

In order to mitigate risks of stocking out in 2022, co-financing obligation associated with this programme should be fulfilled by January 31st 2022